πŸ‡ΊπŸ‡Έ FDA
Patent

US 9624211

Anti-cancer compounds

granted A61KA61K31/352A61K31/4184

Quick answer

US patent 9624211 (Anti-cancer compounds) held by The Board of Regents of the University of Texas System expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/352, A61K31/4184, A61K31/423, A61K31/428